iCAD (ICAD) 10-Q 9 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 07, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	ICAD
Entity Registrant Name	ICAD INC
Entity Central Index Key	749,660
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		16,594,678

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 7,684	$ 8,585
Trade accounts receivable, net of allowance for doubtful accounts of $204 in 2017 and $172 in 2016	5,477	5,189
Inventory, net	3,481	3,727
Prepaid expenses and other current assets	421	1,128
Assets held for sale		1,304
Total current assets	17,063	19,933
Property and equipment, net of accumulated depreciation of $7,006 in 2017 and $6,538 in 2016	1,138	1,385
Other assets	403	53
Intangible assets, net of accumulated amortization of $7,781 in 2017 and $7,518 in 2016	2,922	3,183
Goodwill	14,097	14,097
Total assets	35,623	38,651
Current liabilities:
Accounts payable	946	1,577
Accrued and other expenses	4,488	4,988
Lease payable-current portion		86
Liabilities held for sale		832
Deferred revenue	5,088	5,372
Total current liabilities	10,522	12,855
Other long-term liabilities	153	83
Deferred revenue, long-term portion	508	668
Deferred tax	11	7
Total liabilities	11,194	13,613
Commitments and Contingencies (Note 6 and 8)
Stockholders' equity:
Preferred stock, $ .01 par value: authorized 1,000,000 shares; none issued.
Common stock, $ .01 par value: authorized 30,000,000 shares; issued 16,593,928 in 2017 and 16,260,663 in 2016; outstanding 16,408,097 in 2017 and 16,074,832 in 2016	166	163
Additional paid-in capital	216,375	213,899
Accumulated deficit	(190,697)	(187,609)
Treasury stock at cost, 185,831 shares in 2017 and 2016	(1,415)	(1,415)
Total stockholders' equity	24,429	25,038
Total liabilities and stockholders' equity	$ 35,623	$ 38,651

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable	$ 204	$ 172
Property and equipment, accumulated depreciation and amortization	7,006	6,538
Intangible assets, accumulated amortization	$ 7,781	$ 7,518
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	16,593,928	16,260,663
Common stock, shares outstanding	16,408,097	16,074,832
Treasury stock, shares	185,831	185,831

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue:
Products	$ 2,668	$ 3,418	$ 5,799	$ 5,446
Service and supplies	3,741	3,951	7,401	7,961
Total revenue	6,409	7,369	13,200	13,407
Cost of revenue:
Products	293	185	713	375
Service and supplies	1,327	1,182	2,711	2,541
Amortization and depreciation	286	300	584	603
Total cost of revenue	1,906	1,667	4,008	3,519
Gross profit	4,503	5,702	9,192	9,888
Operating expenses:
Engineering and product development	2,232	2,204	4,806	4,475
Marketing and sales	2,690	2,561	5,592	5,057
General and administrative	2,089	2,177	4,123	3,803
Amortization and depreciation	116	293	238	579
Gain on sale of MRI assets			(2,508)
Total operating expenses	7,127	7,235	12,251	13,914
Loss from operations	(2,624)	(1,533)	(3,059)	(4,026)
Interest expense	(10)	(21)	(15)	(44)
Other income		2		7
Other expense, net	(10)	(19)	(15)	(37)
Loss before income tax expense	(2,634)	(1,552)	(3,074)	(4,063)
Tax benefit (expense)	3	(23)	(14)	(45)
Net loss and comprehensive loss	$ (2,631)	$ (1,575)	$ (3,088)	$ (4,108)
Net loss per share:
Basic	$ (0.16)	$ (0.10)	$ (0.19)	$ (0.26)
Diluted	$ (0.16)	$ (0.10)	$ (0.19)	$ (0.26)
Weighted average number of shares used in computing loss per share:
Basic	16,310	15,904	16,223	15,865
Diluted	16,310	15,904	16,223	15,865

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flow from operating activities:
Net loss	$ (3,088)	$ (4,108)
Adjustments to reconcile net loss to net cash used for by operating activities:
Amortization	264	500
Depreciation	558	682
Bad debt provision	34	102
Stock-based compensation expense	2,570	1,202
Amortization of debt discount and debt costs	(9)	(4)
Interest on settlement obligations	26	46
Deferred tax liability	4
Gain from acquisition litigation settlement		(249)
Loss on disposal of assets	20	9
Gain on sale of MRI assets	(2,508)
Changes in operating assets and liabilities (net of the effect of acquisitions):
Accounts receivable	(690)	1,412
Inventory	248	(152)
Prepaid and other current assets	1,057	(378)
Accounts payable	(631)	(100)
Accrued expenses	(457)	(689)
Deferred revenue	(648)	(1,236)
Total adjustments	(162)	1,145
Net cash used for operating activities	(3,250)	(2,963)
Cash flow from investing activities:
Additions to patents, technology and other	(2)	(3)
Additions to property and equipment	(330)	(223)
Acquisition of VuComp M-Vu CAD		(6)
Sale of MRI assets	2,850
Net cash provided by (used for) investing activities	2,518	(232)
Cash flow from financing activities:
Stock option exercises	30	10
Taxes paid related to restricted stock issuance	(122)	(65)
Principal payments of capital lease obligations	(77)	(562)
Net cash used for financing activities	(169)	(617)
Decrease in cash and equivalents	(901)	(3,812)
Cash and equivalents, beginning of period	8,585	15,280
Cash and equivalents, end of period	7,684	11,468
Supplemental disclosure of cash flow information:
Interest paid	3	50
Taxes paid	$ 45	$ 49

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Note 1 – Basis of Presentation and Significant Accounting Policies The accompanying condensed consolidated financial statements of iCAD, Inc. and subsidiaries (“iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at June 30, 2017, the results of operations of the Company for the three and six month periods ended June 30, 2017 and 2016, and cash flows of the Company for the six month periods ended June 30, 2017 and 2016. Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (“SEC”). The accompanying financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K Segments The Company reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of our advanced image analysis and workflow products. The Therapy segment consists of our radiation therapy (“Axxent”) products, physics and management services, development fees, supplies, and fees for the AxxentHub software platform. Revenue Recognition The Company recognizes revenue primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement. The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, 2009-13”) No. 2009-14, 2009-14”) 985-605, 985-605”). The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references. If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process. The Company has determined that iCAD’s digital and film based sales generally follow the guidance of FASB ASC Topic 605 “Revenue Recognition” (“ASC 605”) as the software has been considered essential to the functionality of the product per the guidance of ASU 2009-14. 2009-13. Revenue from certain CAD products is recognized in accordance with ASC 985-605. The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with ASC 985-605-25-71. Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, Cost of Revenue Cost of revenue consists of the costs of products purchased for resale, costs relating to service including personnel costs for physicists, management services and radiation therapists, costs of service contracts to maintain equipment after the warranty period, product installation, training, customer support, certain warranty repair costs, inbound freight and duty, cost of supplies, manufacturing, warehousing, material movement, inspection, scrap, rework, amortization, depreciation and in-house

Loss per Common Share

Loss per Common Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Loss per Common Share	Note 2 – Loss per Common Share The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts): Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Net loss $ (2,631 ) $ (1,575 ) $ (3,088 ) $ (4,108 ) Basic and diluted shares used in the calculation of net loss per share 16,310 15,904 16,223 15,865 Effect of dilutive securities: Stock options — — — — Restricted stock — — — — Diluted shares used in the calculation of net loss per share 16,310 15,904 16,223 15,865 Net loss per share—basic and diluted $ (0.16 ) $ (0.10 ) $ (0.19 ) $ (0.26 ) Net loss per share—diluted $ (0.16 ) $ (0.10 ) $ (0.19 ) $ (0.26 ) The shares of the Company’s common stock, issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: Period Ended June 30, 2017 2016 Stock options 1,419,540 1,570,332 Restricted stock 384,323 352,980 Stock options and restricted stock 1,803,863 1,923,312

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Business Combinations	Note 3 – Business Combinations Acquisition of VuComp Cancer detection portfolio On January 13, 2016, the Company completed the acquisition of the VuCOMP cancer detection portfolio, including the M-Vu Business Combinations The Company acquired VuComp’s M-Vu Amount (000’s) Cash $ 6 Acquisition litigation settlement 249 Purchase price $ 255 The amount allocated to the acquired assets was estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under this method include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. The following is a summary of the preliminary allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life: Amount (000’s) Estimated amortizable Current assets $ 84 Property and equipment 65 3 Years Identifiable intangible assets 699 1-10 Years Goodwill 293 Current liabilities (280 ) Long-term liabilities (606 ) Purchase price $ 255 The assets obtained in the acquisition of VuComp’s M-Vu M-Vu

Sale of MRI Assets

Sale of MRI Assets	6 Months Ended
	Jun. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]
Sale of MRI Assets	Note 4 – Sale of MRI Assets In December 2016, the Company entered into an Asset Purchase Agreement with Invivo Corporation. In accordance with the agreement, the Company sold to Invivo all right, title and interest to certain intellectual property relating to the Company’s VersaVue Software and DynaCAD product and related assets for $3.2 million. The Company closed the transaction on January 30, 2017 less a holdback reserve of $350,000 for a net of approximately $2.9 million. The holdback reserve of $350,000 has been recorded as an asset in other assets and will be paid to the Company within eighteen months from the closing date, less any amounts, if any, due and payable or reserved under the indemnification provisions in the Asset Purchase agreement. The Company determined the sale constituted the sale of a business in accordance with ASC 805. The Company performed an evaluation to determine if the sale constituted discontinued operations and concluded that the sale did not represent a major strategic shift, and accordingly it was not considered to be discontinued operations. In connection with the transaction, the Company allocated $394,000 of goodwill which was a component of the gain on the sale. The allocation was based on the fair value of the assets sold relative to the fair value of the Detection reporting unit as of the date of the agreement, based on the guidance from ASC 350-20-40-3. The value of the net assets sold is as follows (in thousands): Assets Accounts Receivable $ 116 Intangible assets 810 Allocated Goodwill 394 Total Assets $ 1,320 Liabilities Deferred Revenue $ 746 Total Liabilities $ 746 Net Assets Sold $ 574 In connection with the sale the Company agreed to provide certain transition services to Invivo. The fair value of the transition services were determined based on the cost to provide plus a reasonable profit margin and have been recognized as revenue over the term of approximately ninety days from the closing date. The Company recorded a gain of $2.5 million as of January 30, 2017. The components of the gain on the sale are as follows (in thousands): Gain on Sale Cash received $ 2,850 Holdback reserve 350 Fair value of transition services (118 ) Net Assets sold (574 ) Total $ 2,508

Inventory

Inventory	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventory	Note 5 – Inventory The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows (in thousands): as of June 30, as of December 31, Raw materials $ 2,181 $ 2,503 Work in process 102 75 Finished Goods 1,198 1,149 Inventory $ 3,481 $ 3,727

Lease Commitments

Lease Commitments	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Lease Commitments	Note 6 – Lease Commitments Operating leases Facilities are leased under operating leases expiring at various dates through March 2020. Certain of these leases contain renewal options. Rent expense under operating leases was $221,000 and $436,000 for the three and six months ended June 30, 2017, respectively and $176,000 and $338,000 for the three and six months ended June 30, 2016, respectively. Future minimum lease payments as of June 30, 2017 under operating leases are as follows: (in thousands) Fiscal Year Operating 2017 $ 318 2018 738 2019 746 2020 174 Total $ 1,976 Capital leases In connection with the Radion/DermEbx Acquisition which closed in July 2014, the Company assumed two separate equipment lease obligations with payments totaling approximately $2.6 million through May 2017. The leases were determined to be capital leases and accordingly the equipment was capitalized and a liability of $2.5 million was recorded. In connection with the acquisition, the Company recorded a fair value adjustment to interest expense and amortized the adjustment over the life of the related lease. As of June 30, 2017, there was no further liability for the acquired equipment leases. Related Party Lease: Kamal Gogineni is an employee of one of the Company’s subsidiaries and a stockholder of the Company’s common stock. Additionally, Mr. Gogineni is a shareholder of Radion Capital Partners (“RCP”). RCP was the lessor under a lease between RCP and DermEbx (the “Lease”). In connection with the Company’s acquisition of assets of Radion, Inc. and DermEbx that closed in July 2014, one of the assets and obligations that the Company acquired was the Lease. Pursuant to the Lease, the Company paid approximately $76,000 to RCP in 2017. As of June 30, 2017, there is no further obligation.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Note 7 – Stock-Based Compensation The Company follows the guidance in ASC Topic 718, “ Compensation – Stock Compensation , The Company granted options to purchase 47,615 shares of the Company’s stock in the three months ended June 30, 2017. Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Average risk-free interest rate 1.50 % 0.92 % 1.49 % 0.92 % Expected dividend yield None None None None Expected life 3.5 years 3.5 years 3.5 years 3.5 years Expected volatility 64.9% to 67.0% 68.6 % 64.9% to 72.0% 68.6% to 75.3% Weighted average exercise price $ 4.21 $ 6.01 $ 4.46 $ 5.94 Weighted average fair value $ 1.98 $ 2.93 $ 2.19 $ 2.90 The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Cost of revenue $ 2 $ 1 $ 4 $ 4 Engineering and product development 352 97 557 207 Marketing and sales 499 141 722 314 General and administrative 748 313 1,287 677 $ 1,601 $ 552 $ 2,570 $ 1,202 As of June 30, 2017, unrecognized compensation cost (in thousands) related to unexercisable options and unvested restricted stock and the weighted average remaining period is as follows: Remaining expense $ 2,566 Weighted average term 0.6 years The Company’s restricted stock awards typically vest in either one year or three equal annual installments with the first installment vesting one year from grant date. The Company granted a total of 162,500 shares of performance based restricted stock during 2016 with performance measured on meeting a revenue target based on growth for fiscal year 2017 and vesting in three equal installments with the first installment vesting upon measurement of the goal. In addition, a maximum of 108,333 additional shares are available to be earned based on exceeding the revenue goal. Assumptions used to determine the value of performance based grants of restricted stock include the probability of achievement of the specified revenue targets. Compensation cost for performance based restricted stock requires significant judgment regarding probability of achieving the performance objectives and compensation cost is re-measured The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands): Period Ended June 30, Aggregate intrinsic value 2017 2016 Stock options $ 966 $ 1,945 Restricted stock 1,610 1,843 The intrinsic value of stock options exercised during the three and six months ended June 30, 2017 was $17,000 and $38,000, respectively. The intrinsic value of stock options exercised during the three and six months June 30, 2016 was $0 and $6,000, respectively. The intrinsic value of restricted shares that vested in the three and six months ended June 30, 2017 was $1.2 million and $1.5 million, respectively. During the quarter ended June 30, 2017 there were 204,756 shares that were awarded and vested in the quarter. The intrinsic value of restricted shares that vested in the three and six months ended June 30, 2016 was $0.3 million and $1.0 million, respectively.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8 – Commitments and Contingencies Foreign Tax Claim In July 2007, a dissolved former Canadian subsidiary of the Company, CADx Medical Systems Inc. (“CADx Medical”), received a tax re-assessment re-assessment re-assessment Settlement Obligations In connection with the acquisition of Xoft in 2010, the Company recorded a royalty obligation pursuant to a settlement agreement entered into between Xoft and Hologic in August 2007. Xoft received a nonexclusive, irrevocable, perpetual, worldwide license, including the right to sublicense certain Hologic patents, and a non-compete In December, 2011, the Company agreed to a settlement related to litigation with Carl Zeiss Meditec AG. As of June 30, 2017, the remaining liability recorded within accrued expenses was $500,000, and the amount was paid in July 2017. The Company recorded interest expense of approximately $13,000 and $26,000 in the three and six months ended June 30, 2017, respectively and $13,000 and $26,000 in the three and six months ended June 30, 2016, respectively related to this obligation. Other Commitments The Company is obligated to pay approximately $0.7 million for firm purchase obligations to suppliers for future product deliverables. Litigation The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 9 – Fair Value Measurements The Company follows the provisions of ASC Topic 820, “ Fair Value Measurement and Disclosures • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and certain accrued liabilities. The carrying amounts of our cash and cash equivalents (which are composed primarily of deposit and overnight sweep accounts), accounts receivable, accounts payable and certain accrued liabilities approximate fair value due to the short maturity of these instruments. The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts. The Company’s money market funds are included in cash and cash equivalents in the accompanying balance sheets and are considered a Level 1 investment as they are valued at quoted market prices in active markets. The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy. Fair value measurements using: (000’s) as of December 31, 2016 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 6,622 $ — $ — $ 6,622 Total Assets $ 6,622 $ — $ — $ 6,622 Fair value measurements using: (000’s) as of June 30, 2017 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 6,225 $ — $ — $ 6,225 Total Assets $ 6,225 $ — $ — $ 6,225

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 10 – Income Taxes The Company recorded an income tax benefit of $3,000 and a provision of $14,000 for the three and six months ended June 30, 2017, respectively and a provision of $23,000 and $45,000 for the three and six months ended June 30, 2016, respectively. The tax benefit for the quarter ended June 30, 2017 is the result of applying for research and development credits in New Hampshire. In the second quarter of 2017, the Company applied for $50,000 of research and development credits from New Hampshire. The Company anticipates the credits to be allocated for the 2016 tax year as well the 2017 tax year. The research and development credits have been utilized to decrease the New Hampshire non-income No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting 2016-09”). 2016-09,

Long-lived assets

Long-lived assets	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Long-lived assets	Note 11 – Long-lived assets In accordance with FASB ASC Topic 360, “Property, Plant and Equipment” (“ASC 360”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group. ASC 360-10-35 360-10-35-21 • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group). The Company did not have any triggering events in the quarter ended June 30, 2017.

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Note 12 – Goodwill In accordance with FASB ASC Topic 350-20, 350-20”), Factors the Company considers important, which could trigger an impairment of such asset, include the following: • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value. The Company would record an impairment charge if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. In evaluating potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of reporting units. The Company makes assumptions about future cash flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made. The Company did not have any triggering events in the quarter ended June 30, 2017. The Company performed an annual impairment assessment at October 1, 2016 and compared the fair value of each reporting unit to its carrying value as of this date. Fair value was approximately 816% of carrying value for the Detection reporting unit and 126% of carrying value for the Therapy reporting unit. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units’ revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment. The Company determined the fair values for each reporting unit using a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company used internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in the forecasts. The discount rate of approximately 15% is derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts. In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as market data may not be available for divisions within larger conglomerates or non-public The Company corroborated the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to the business profile of the Company, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. In addition, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not be reflected in an observable market price. The Company will assess each valuation methodology based upon the relevance and availability of the data at the time the valuation is performed and weight the methodologies appropriately. As discussed in Note 3, in April 2015, the Company acquired VuComp’s M-Vu ® M-Vu In December 2016, the Company entered into an Asset Purchase Agreement with Invivo Corporation. The Company sold and conveyed to Buyer all right, title and interest to certain intellectual property relating to the VersaVue Software and the DynaCAD product and related assets. As a result of the Asset Purchase Agreement, the Company determined that the sale constituted the sale of a business and the Company allocated $394,000 of goodwill to assets held for sale as of December 31, 2016. The allocation was based on the fair value of the assets sold relative to the fair value of the Detection reporting unit as of the date of the Asset Purchase Agreement. The Company closed the transaction on January 30, 2017, and goodwill was a component of the net assets sold as of the closing date. A roll forward of goodwill activity by reportable segment is as follows (in thousands): Detection Therapy Total Accumulated Goodwill $ — $ — $ 47,937 Accumulated impairment — — (26,828 ) Fair value allocation 7,663 13,446 — Acquisition of DermEbx and Radion — 6,154 6,154 Acquisition measurement period adjustments — 116 116 Acquisition of VuComp 800 — 800 Impairment — (13,981 ) (13,981 ) Balance at December 31, 2015 8,463 5,735 14,198 Acquisition of VuComp 293 — 293 Sale of MRI assets (394 ) — (394 ) Balance at December 31, 2016 8,362 5,735 14,097 — — — Balance at June 30, 2017 $ 8,362 $ 5,735 $ 14,097 Accumulated Goodwill 699 6,270 54,906 Fair value allocation 7,663 13,446 — Accumulated impairment — (13,981 ) (40,809 ) Balance at June 30, 2017 $ 8,362 $ 5,735 $ 14,097

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment Reporting	Note 13 – Segment Reporting In accordance with FASB Topic ASC 280, “ Segments The Company’s CODM is the CEO. Each segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments, Cancer Detection and Cancer Therapy. The Detection segment consists of our advanced image analysis and workflow products, and the Therapy segment consists of our radiation therapy Axxent products, and related services. The primary factors used by our CODM to allocate resources are based on revenues, gross profit, operating income, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring Our CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Segment revenues: Detection $ 4,231 $ 4,897 $ 8,720 $ 8,827 Therapy 2,178 2,472 4,480 4,580 Total Revenue $ 6,409 $ 7,369 $ 13,200 $ 13,407 Segment gross profit: Detection $ 3,730 $ 4,394 $ 7,731 $ 7,843 Therapy 773 1,308 1,461 2,045 Segment gross profit $ 4,503 $ 5,702 $ 9,192 $ 9,888 Segment operating income (loss): Detection 1,284 2,042 2,786 3,244 Therapy (1,793 ) (1,336 ) (4,176 ) (3,343 ) Segment operating income (loss) $ (509 ) $ 706 $ (1,390 ) $ (99 ) General, administrative, depreciation and amortization expense $ (2,115 ) $ (2,239 ) $ (4,177 ) $ (3,927 ) Interest expense (10 ) (21 ) (15 ) (44 ) Gain on sale of MRI assets — — 2,508 — Other income — 2 — 7 Loss before income tax $ (2,634 ) $ (1,552 ) $ (3,074 ) $ (4,063 )

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2017
Text Block [Abstract]
Recent Accounting Pronouncements	Note 14 – Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606), or ASU 2014-09, which superseded nearly all existing revenue recognition guidance under U.S. GAAP. Since then, the FASB has also issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606), Principals versus Agent Considerations and ASU 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, which further elaborate on the original ASU No. 2014-09. The core principle of these updates is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgments and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. In July 2015, the FASB approved a one-year deferral of the effective date to January 1, 2018, with early adoption to be permitted as of the original effective date of January 1, 2017. Once this standard becomes effective, companies may use either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are concluding our detailed assessment phase of implementing this guidance. We do not expect that our revenue recognition will be materially impacted by this new guidance. Once we conclude our assessment and begin our implementation and recast phase, we will finalize the transition method to be applied upon adoption. There are also certain considerations related to internal control over financial reporting that are associated with implementing Topic 606. We are also evaluating our internal control framework over revenue recognition to identify any changes that may need to be made in response to the new guidance. In addition, disclosure requirements under the new guidance in Topic 606 have been significantly expanded in comparison to the disclosure requirements under the current guidance. The Company’s implementation phase will include designing and implementing the appropriate controls to obtain and disclose the information required under Topic 606. In February 2016, the FASB issued ASU No. 2016-02, right-of-use off-balance On January 1, 2017, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-09, 2016-09”), 2016-09, In August 2016, the FASB issued ASU 2016-15,

Basis of Presentation and Sig20

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Revenue Recognition	Revenue Recognition The Company recognizes revenue primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement. The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, 2009-13”) No. 2009-14, 2009-14”) 985-605, 985-605”). The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references. If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process. The Company has determined that iCAD’s digital and film based sales generally follow the guidance of FASB ASC Topic 605 “Revenue Recognition” (“ASC 605”) as the software has been considered essential to the functionality of the product per the guidance of ASU 2009-14. 2009-13. Revenue from certain CAD products is recognized in accordance with ASC 985-605. The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with ASC 985-605-25-71. Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20,
Cost of Revenue	Cost of Revenue Cost of revenue consists of the costs of products purchased for resale, costs relating to service including personnel costs for physicists, management services and radiation therapists, costs of service contracts to maintain equipment after the warranty period, product installation, training, customer support, certain warranty repair costs, inbound freight and duty, cost of supplies, manufacturing, warehousing, material movement, inspection, scrap, rework, amortization, depreciation and in-house
Compensation - Stock Compensation	The Company follows the guidance in ASC Topic 718, “ Compensation – Stock Compensation ,
Litigation	Litigation The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.
Fair Value Measurement and Disclosures	Fair Value Measurements The Company follows the provisions of ASC Topic 820, “ Fair Value Measurement and Disclosures • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and certain accrued liabilities. The carrying amounts of our cash and cash equivalents (which are composed primarily of deposit and overnight sweep accounts), accounts receivable, accounts payable and certain accrued liabilities approximate fair value due to the short maturity of these instruments. The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts. The Company’s money market funds are included in cash and cash equivalents in the accompanying balance sheets and are considered a Level 1 investment as they are valued at quoted market prices in active markets. The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy.
Income Taxes	Income Taxes The Company recorded an income tax benefit of $3,000 and a provision of $14,000 for the three and six months ended June 30, 2017, respectively and a provision of $23,000 and $45,000 for the three and six months ended June 30, 2016, respectively. The tax benefit for the quarter ended June 30, 2017 is the result of applying for research and development credits in New Hampshire. In the second quarter of 2017, the Company applied for $50,000 of research and development credits from New Hampshire. The Company anticipates the credits to be allocated for the 2016 tax year as well the 2017 tax year. The research and development credits have been utilized to decrease the New Hampshire non-income No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting 2016-09”). 2016-09,
Long-lived assets	In accordance with FASB ASC Topic 360, “Property, Plant and Equipment” (“ASC 360”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group. ASC 360-10-35 360-10-35-21 • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group). The Company did not have any triggering events in the quarter ended June 30, 2017.
Intangibles - Goodwill and Other	In accordance with FASB ASC Topic 350-20, 350-20”),
Segment Reporting	In accordance with FASB Topic ASC 280, “ Segments
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606), or ASU 2014-09, which superseded nearly all existing revenue recognition guidance under U.S. GAAP. Since then, the FASB has also issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606), Principals versus Agent Considerations and ASU 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, which further elaborate on the original ASU No. 2014-09. The core principle of these updates is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgments and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. In July 2015, the FASB approved a one-year deferral of the effective date to January 1, 2018, with early adoption to be permitted as of the original effective date of January 1, 2017. Once this standard becomes effective, companies may use either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are concluding our detailed assessment phase of implementing this guidance. We do not expect that our revenue recognition will be materially impacted by this new guidance. Once we conclude our assessment and begin our implementation and recast phase, we will finalize the transition method to be applied upon adoption. There are also certain considerations related to internal control over financial reporting that are associated with implementing Topic 606. We are also evaluating our internal control framework over revenue recognition to identify any changes that may need to be made in response to the new guidance. In addition, disclosure requirements under the new guidance in Topic 606 have been significantly expanded in comparison to the disclosure requirements under the current guidance. The Company’s implementation phase will include designing and implementing the appropriate controls to obtain and disclose the information required under Topic 606. In February 2016, the FASB issued ASU No. 2016-02, right-of-use off-balance On January 1, 2017, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-09, 2016-09”), 2016-09, In August 2016, the FASB issued ASU 2016-15,

Loss per Common Share (Tables)

Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Calculation of Net Loss Per Share	A summary of the Company’s calculation of net loss per share is as follows (in thousands except per share amounts): Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Net loss $ (2,631 ) $ (1,575 ) $ (3,088 ) $ (4,108 ) Basic and diluted shares used in the calculation of net loss per share 16,310 15,904 16,223 15,865 Effect of dilutive securities: Stock options — — — — Restricted stock — — — — Diluted shares used in the calculation of net loss per share 16,310 15,904 16,223 15,865 Net loss per share—basic and diluted $ (0.16 ) $ (0.10 ) $ (0.19 ) $ (0.26 ) Net loss per share—diluted $ (0.16 ) $ (0.10 ) $ (0.19 ) $ (0.26 )
Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	The shares of the Company’s common stock, issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: Period Ended June 30, 2017 2016 Stock options 1,419,540 1,570,332 Restricted stock 384,323 352,980 Stock options and restricted stock 1,803,863 1,923,312

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2017
MVu Breast Density [Member]
Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and Liabilities Assumed	As a result the Company recorded a gain on litigation settlement of $249,000 in general and administrative expenses during the first quarter of 2016, which is a component of the purchase price as noted below: Amount (000’s) Cash $ 6 Acquisition litigation settlement 249 Purchase price $ 255
VuComp Cancer Detection Portfolio [Member]
Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following is a summary of the preliminary allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life: Amount (000’s) Estimated amortizable Current assets $ 84 Property and equipment 65 3 Years Identifiable intangible assets 699 1-10 Years Goodwill 293 Current liabilities (280 ) Long-term liabilities (606 ) Purchase price $ 255

Sale of MRI Assets (Tables)

Sale of MRI Assets (Tables)	6 Months Ended
	Jun. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Net Assets Sold	The value of the net assets sold is as follows (in thousands): Assets Accounts Receivable $ 116 Intangible assets 810 Allocated Goodwill 394 Total Assets $ 1,320 Liabilities Deferred Revenue $ 746 Total Liabilities $ 746 Net Assets Sold $ 574
Schedule of Components of Gain on Sale	The components of the gain on the sale are as follows (in thousands): Gain on Sale Cash received $ 2,850 Holdback reserve 350 Fair value of transition services (118 ) Net Assets sold (574 ) Total $ 2,508

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Components of Inventory	The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows (in thousands): as of June 30, as of December 31, Raw materials $ 2,181 $ 2,503 Work in process 102 75 Finished Goods 1,198 1,149 Inventory $ 3,481 $ 3,727

Lease Commitments (Tables)

Lease Commitments (Tables)	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments under Operating Leases	Future minimum lease payments as of June 30, 2017 under operating leases are as follows: (in thousands) Fiscal Year Operating 2017 $ 318 2018 738 2019 746 2020 174 Total $ 1,976

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values	Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Average risk-free interest rate 1.50 % 0.92 % 1.49 % 0.92 % Expected dividend yield None None None None Expected life 3.5 years 3.5 years 3.5 years 3.5 years Expected volatility 64.9% to 67.0% 68.6 % 64.9% to 72.0% 68.6% to 75.3% Weighted average exercise price $ 4.21 $ 6.01 $ 4.46 $ 5.94 Weighted average fair value $ 1.98 $ 2.93 $ 2.19 $ 2.90
Stock-Based Compensation Expense Including Options and Restricted Stock by Category	The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Cost of revenue $ 2 $ 1 $ 4 $ 4 Engineering and product development 352 97 557 207 Marketing and sales 499 141 722 314 General and administrative 748 313 1,287 677 $ 1,601 $ 552 $ 2,570 $ 1,202
Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period	As of June 30, 2017, unrecognized compensation cost (in thousands) related to unexercisable options and unvested restricted stock and the weighted average remaining period is as follows: Remaining expense $ 2,566 Weighted average term 0.6 years
Aggregate Intrinsic Value	The Company’s aggregate intrinsic value for stock options and restricted stock outstanding is as follows (in thousands): Period Ended June 30, Aggregate intrinsic value 2017 2016 Stock options $ 966 $ 1,945 Restricted stock 1,610 1,843

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Assets and Liabilities which are Measured at Fair Value on a Recurring Basis	The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy. Fair value measurements using: (000’s) as of December 31, 2016 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 6,622 $ — $ — $ 6,622 Total Assets $ 6,622 $ — $ — $ 6,622 Fair value measurements using: (000’s) as of June 30, 2017 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 6,225 $ — $ — $ 6,225 Total Assets $ 6,225 $ — $ — $ 6,225

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Roll Forward of Goodwill Activity by Reportable Segment	A roll forward of goodwill activity by reportable segment is as follows (in thousands): Detection Therapy Total Accumulated Goodwill $ — $ — $ 47,937 Accumulated impairment — — (26,828 ) Fair value allocation 7,663 13,446 — Acquisition of DermEbx and Radion — 6,154 6,154 Acquisition measurement period adjustments — 116 116 Acquisition of VuComp 800 — 800 Impairment — (13,981 ) (13,981 ) Balance at December 31, 2015 8,463 5,735 14,198 Acquisition of VuComp 293 — 293 Sale of MRI assets (394 ) — (394 ) Balance at December 31, 2016 8,362 5,735 14,097 — — — Balance at June 30, 2017 $ 8,362 $ 5,735 $ 14,097 Accumulated Goodwill 699 6,270 54,906 Fair value allocation 7,663 13,446 — Accumulated impairment — (13,981 ) (40,809 ) Balance at June 30, 2017 $ 8,362 $ 5,735 $ 14,097

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss	Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Segment revenues: Detection $ 4,231 $ 4,897 $ 8,720 $ 8,827 Therapy 2,178 2,472 4,480 4,580 Total Revenue $ 6,409 $ 7,369 $ 13,200 $ 13,407 Segment gross profit: Detection $ 3,730 $ 4,394 $ 7,731 $ 7,843 Therapy 773 1,308 1,461 2,045 Segment gross profit $ 4,503 $ 5,702 $ 9,192 $ 9,888 Segment operating income (loss): Detection 1,284 2,042 2,786 3,244 Therapy (1,793 ) (1,336 ) (4,176 ) (3,343 ) Segment operating income (loss) $ (509 ) $ 706 $ (1,390 ) $ (99 ) General, administrative, depreciation and amortization expense $ (2,115 ) $ (2,239 ) $ (4,177 ) $ (3,927 ) Interest expense (10 ) (21 ) (15 ) (44 ) Gain on sale of MRI assets — — 2,508 — Other income — 2 — 7 Loss before income tax $ (2,634 ) $ (1,552 ) $ (3,074 ) $ (4,063 )

Basis of Presentation and Sig30

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)	3 Months Ended	6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2017Segment	Jun. 30, 2016USD ($)
Basis Of Presentation And Significant Accounting Policies [Abstract]
Business segment | Segment		2
Medical Device Excise tax included in the cost of revenue | $	$ 329,000		$ 467,000

Loss per Common Share - Calcula

Loss per Common Share - Calculation of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net loss	$ (2,631)	$ (1,575)	$ (3,088)	$ (4,108)
Basic and diluted shares used in the calculation of net loss per share	16,310	15,904	16,223	15,865
Effect of dilutive securities:
Diluted shares used in the calculation of net loss per share	16,310	15,904	16,223	15,865
Net loss per share-basic and diluted	$ (0.16)	$ (0.10)	$ (0.19)	$ (0.26)
Net loss per share-diluted	$ (0.16)	$ (0.10)	$ (0.19)	$ (0.26)
Stock Options [Member]
Effect of dilutive securities:
Incremental common shares attributable to share-based payment arrangements	0	0	0	0
Restricted Stock [Member]
Effect of dilutive securities:
Incremental common shares attributable to share-based payment arrangements	0	0	0	0

Loss per Common Share - Schedul

Loss per Common Share - Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	1,803,863	1,923,312
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	1,419,540	1,570,332
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	384,323	352,980

Business Combinations - Acquisi

Business Combinations - Acquisition of VuComp Cancer Detection Portfolio - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016USD ($)
MVu Breast Density [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Gain on litigation settlement	$ 249,000

Business Combinations - Allocat

Business Combinations - Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and liabilities Assumed (Detail) - USD ($) $ in Thousands	Jan. 13, 2016	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill		$ 14,097	$ 14,097	$ 14,198
MVu Breast Density [Member]
Business Acquisition [Line Items]
Cash	$ 6
Acquisition litigation settlement	249
Purchase price	255
VuComp Cancer Detection Portfolio [Member]
Business Acquisition [Line Items]
Current assets	84
Property and equipment	65
Identifiable intangible assets	699
Goodwill	293
Current liabilities	(280)
Long-term liabilities	(606)
Purchase price	$ 255
Property and equipment, Estimated amortizable life	3 years
VuComp Cancer Detection Portfolio [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated amortizable life	1 year
VuComp Cancer Detection Portfolio [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated amortizable life	10 years

Sale of MRI Assets - Additional

Sale of MRI Assets - Additional Information (Detail) - USD ($)	Jan. 30, 2017	Jun. 30, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Allocation of goodwill to asset held for sale			$ 394,000
VersaVue Software and DynaCAD Product and Related Assets [Member] | Asset Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale and transfer of intangible assets			$ 3,200,000
Holdback reserve related to sale and transfer of intangible assets	$ 350,000	$ 350,000
Proceeds from sale and transfer of intangible assets	2,900,000
Allocation of goodwill to asset held for sale		394,000
Gain on sale and transfer of intangible assets	$ 2,500,000	$ 2,508,000

Sale of MRI Assets - Schedule o

Sale of MRI Assets - Schedule of Net Assets Sold (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Assets
Allocated Goodwill		$ 394,000
Total Assets		1,304,000
Liabilities
Total Liabilities		$ 832,000
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | VersaVue Software and DynaCAD Product and Related Assets [Member]
Assets
Accounts Receivable	$ 116,000
Intangible assets	810,000
Allocated Goodwill	394,000
Total Assets	1,320,000
Liabilities
Deferred Revenue	746,000
Total Liabilities	746,000
Net Assets Sold	$ 574,000

Sale of MRI Assets - Schedule37

Sale of MRI Assets - Schedule of Components of Gain on Sale (Detail) - USD ($)	Jan. 30, 2017	Jun. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash received		$ 2,850,000
Asset Purchase Agreement [Member] | VersaVue Software and DynaCAD Product and Related Assets [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash received		2,850,000
Holdback reserve	$ 350,000	350,000
Fair value of transition services		(118,000)
Net Assets sold		(574,000)
Total	$ 2,500,000	$ 2,508,000

Inventory - Components of Inven

Inventory - Components of Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 2,181	$ 2,503
Work in process	102	75
Finished Goods	1,198	1,149
Inventory	$ 3,481	$ 3,727

Lease Commitments - Additional

Lease Commitments - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)LeaseContracts	Jun. 30, 2016USD ($)
Schedule Of Leases [Line Items]
Operating leases expiring description			Facilities are leased under operating leases expiring at various dates through March 2020.
Rent expense	$ 221,000	$ 176,000	$ 436,000	$ 338,000
Payments of capital lease			$ 77,000	$ 562,000
DermEbx and Radion [Member]
Schedule Of Leases [Line Items]
Number of equipment lease obligation | LeaseContracts			2
Assumed capital leases	2,600,000		$ 2,600,000
Liability recorded on capital leases			2,500,000
Outstanding liability on equipment leases	0		0
Payments of capital lease			76,000
Capital lease obligation	$ 0		$ 0

Lease Commitments - Future Mini

Lease Commitments - Future Minimum Lease Payments under Operating Leases (Detail) $ in Thousands	Jun. 30, 2017USD ($)
Leases [Abstract]
2,017	$ 318
2,018	738
2,019	746
2,020	174
Total	$ 1,976

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted	204,756
Number of shares vested	204,756
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value of stock options exercised	$ 17,000	$ 0	$ 38,000	$ 6,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation vesting period			1 year
Aggregate intrinsic value of the options vested in period	$ 1,200,000	$ 300,000	$ 1,500,000	$ 1,000,000
Performance Based Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted			162,500
Performance Based Restricted Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares available for granted			108,333
Time Based Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted	204,756		238,575
Time Based Restricted Stock [Member] | In Lieu of Cash Bonus [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted	172,668
Black Scholes Model [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted	47,615

Stock-Based Compensation - Opti

Stock-Based Compensation - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - Stock Options [Member] - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average risk-free interest rate	1.50%	0.92%	1.49%	0.92%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Expected life	3 years 6 months	3 years 6 months	3 years 6 months	3 years 6 months
Weighted average exercise price	$ 4.21	$ 6.01	$ 4.46	$ 5.94
Weighted average fair value	$ 1.98	$ 2.93	$ 2.19	$ 2.90
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	64.90%	68.60%	64.90%	68.60%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	67.00%		72.00%	75.30%

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense Including Options and Restricted Stock by Category (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 1,601	$ 552	$ 2,570	$ 1,202
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	2	1	4	4
Engineering and Product Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	352	97	557	207
Marketing and Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	499	141	722	314
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 748	$ 313	$ 1,287	$ 677

Stock-Based Compensation - Unre

Stock-Based Compensation - Unrecognized Compensation Cost Related to Unexercisable Options and Unvested Restricted Stock and Weighted Average Remaining Period (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]
Remaining expense	$ 2,566
Weighted average term	7 months 6 days

Stock-Based Compensation - Aggr

Stock-Based Compensation - Aggregate Intrinsic Value (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value, Stock option	$ 966	$ 1,945
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value, Restricted stock	$ 1,610	$ 1,843

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Jul. 31, 2017	Feb. 28, 2010	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Loss Contingencies [Line Items]
Minimum annual royalty payment					$ 250,000
Minimum royalty obligations			$ 448,000		448,000
Accrued expenses, settlement obligation			500,000		500,000
Purchase obligations to suppliers for future product deliverables			700,000		700,000
Hologic [Member]
Loss Contingencies [Line Items]
Interest expense royalty obligation				$ 10,000		$ 20,000
Zeiss [Member]
Loss Contingencies [Line Items]
Interest expense, settlement obligation			$ 13,000	$ 13,000	$ 26,000	$ 26,000
CADx Medical Systems Inc [Member]
Loss Contingencies [Line Items]
Tax re-assessment received	$ 6,800,000
Reduced tax re-assessment received		$ 703,000

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Assets
Total Assets	$ 6,225	$ 6,622
Money Market Accounts [Member]
Assets
Total Assets	6,225	6,622
Level 1 [Member]
Assets
Total Assets	6,225	6,622
Level 1 [Member] | Money Market Accounts [Member]
Assets
Total Assets	$ 6,225	$ 6,622

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Schedule Of Income Tax Expense [Line Items]
Unrecognized tax benefits	$ 0		$ 0
Interest or penalties related to uncertain tax positions	0		$ 0
Company preceding tax years			3 years
Deferred tax liability related to amortized goodwill	10,600		$ 10,600
Deferred tax liability	3,700		3,700
Income tax provision (benefit)	(3,000)	$ 23,000	14,000	$ 45,000
New Hampshire [Member]
Schedule Of Income Tax Expense [Line Items]
Income tax expense research and development	50,000
ASU 2016-09 [Member]
Schedule Of Income Tax Expense [Line Items]
Increase in net operating loss deferred tax assets	$ 2,100,000		$ 2,100,000

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) - USD ($)	Jan. 31, 2016	Apr. 30, 2015	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Line Items]
Percentage of discount derived from capital asset pricing model			15.00%
Business acquisition paid in cash				$ 6,000
Goodwill			$ 14,097,000		$ 14,097,000	$ 14,198,000
Allocation of goodwill to asset held for sale					394,000
VuComp M-Vu Breast Density Product [Member]
Goodwill [Line Items]
Business acquisition paid in cash		$ 1,700,000
VuComp M-Vu CAD [Member]
Goodwill [Line Items]
Business acquisition paid in cash	$ 6,000
Detection [Member]
Goodwill [Line Items]
Percentage of fair value of each reporting unit			816.00%
Goodwill			$ 8,362,000		8,362,000	8,463,000
Detection [Member] | VuComp M-Vu Breast Density Product [Member]
Goodwill [Line Items]
Goodwill			$ 800,000
Detection [Member] | VuComp M-Vu CAD [Member]
Goodwill [Line Items]
Goodwill	$ 293,000
Therapy [Member]
Goodwill [Line Items]
Percentage of fair value of each reporting unit			126.00%
Goodwill			$ 5,735,000		$ 5,735,000	$ 5,735,000

Goodwill - Roll Forward of Good

Goodwill - Roll Forward of Goodwill Activity by Reportable Segment (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Line Items]
Accumulated Goodwill	$ 54,906		$ 47,937
Accumulated impairment	(40,809)		(26,828)
Goodwill Balance	14,097	$ 14,097	14,198
Acquisition measurement period adjustments			116
Sale of MRI assets		(394)
Impairment			(13,981)
DermEbx and Radion [Member]
Goodwill [Line Items]
Acquisition cost			6,154
VuComp M-Vu Breast Density Product [Member]
Goodwill [Line Items]
Acquisition cost		293	800
Detection [Member]
Goodwill [Line Items]
Accumulated Goodwill	699
Fair value allocation	7,663		7,663
Goodwill Balance	8,362	8,362	8,463
Sale of MRI assets		(394)
Detection [Member] | VuComp M-Vu Breast Density Product [Member]
Goodwill [Line Items]
Goodwill Balance	800
Acquisition cost		293	800
Therapy [Member]
Goodwill [Line Items]
Accumulated Goodwill	6,270
Fair value allocation	13,446		13,446
Accumulated impairment	(13,981)
Goodwill Balance	$ 5,735	$ 5,735	5,735
Acquisition measurement period adjustments			116
Impairment			(13,981)
Therapy [Member] | DermEbx and Radion [Member]
Goodwill [Line Items]
Acquisition cost			$ 6,154

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)Segment	Jun. 30, 2016USD ($)
Schedule Of Geographical Information [Line Items]
Number of reporting segments | Segment			2
Total Export Sales	$ 6,409,000	$ 7,369,000	$ 13,200,000	$ 13,407,000
Intersegment Eliminations [Member]
Schedule Of Geographical Information [Line Items]
Total Export Sales			$ 0

Segment Reporting - Summary of

Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment revenues:
Total revenue	$ 6,409	$ 7,369	$ 13,200	$ 13,407
Segment gross profit:
Segment gross profit	4,503	5,702	9,192	9,888
Segment operating income (loss):
Segment operating income (loss)	(509)	706	(1,390)	(99)
General, administrative, depreciation and amortization expense	(2,115)	(2,239)	(4,177)	(3,927)
Interest expense	(10)	(21)	(15)	(44)
Gain on sale of MRI assets			2,508
Other income		2		7
Loss before income tax expense	(2,634)	(1,552)	(3,074)	(4,063)
Detection [Member]
Segment revenues:
Total revenue	4,231	4,897	8,720	8,827
Segment gross profit:
Segment gross profit	3,730	4,394	7,731	7,843
Segment operating income (loss):
Segment operating income (loss)	1,284	2,042	2,786	3,244
Therapy [Member]
Segment revenues:
Total revenue	2,178	2,472	4,480	4,580
Segment gross profit:
Segment gross profit	773	1,308	1,461	2,045
Segment operating income (loss):
Segment operating income (loss)	$ (1,793)	$ (1,336)	$ (4,176)	$ (3,343)

Recent Accounting Pronounceme53

Recent Accounting Pronouncements - Additional Information (Detail) $ in Millions	Jun. 30, 2017USD ($)
ASU 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase in net operating loss deferred tax assets	$ 2.1